Dr. Paul K. Wotton received his Ph.D. in Pharmaceutical Sciences from the University of Nottingham and is an experienced CEO, Board Member, inventor, and serial entrepreneur. Dr. Wotton serves on the Board of Directors of Vericel Corporation (NASDAQ: VCEL) and Cynata Therapeutics (ASX: CYP) and is a Founder of Avenge Bio. Dr. Wotton was recently named as a “Top 100 Innovation CEO” by World Biz Magazine and won the Ernst & Young Entrepreneur of the Year Regional (NJ) Life Sciences award in 2014.
Paulo Garcia, Ph.D. Kytopen Co-Founder and CEO
Dr. Paulo Garcia is a scientist by training and entrepreneur by DNA. Paulo is deeply motivated by our ongoing efforts to help patients suffering from devastating diseases worldwide. As CEO and Co-Founder of Kytopen, he is committed to increase patient access to engineered living medicines through our proprietary Flowfect® technology for non-viral gene delivery into immune cells to enable cost-effective cell and gene therapies. Dr. Garcia earned his Ph.D. at the Virginia Tech - Wake-Forest School of Biomedical Engineering and Sciences. He subsequently completed his Postdoc at the Massachusetts Institute of Technology (MIT) with his Co-Founder Dr. Cullen Buie prior to spinning out Kytopen in 2017.
Cullen Buie, Ph.D. Co-Founder
Cullen R. Buie, Ph.D. is a Tenured Professor of Mechanical Engineering at MIT and co-inventor of the high-throughput genetic modification technology. He brings expertise in the areas of microfluidics, microfabrication, and experimental fluid mechanics to Kytopen.
Ann DeWitt Board Member
Ann is a General Partner at The Engine. She serves as a Board Member for Kytopen, Biobot Analytics, Cellino, Lucy Therapeutics, Quaise, Syzygy, and Vaxess Technologies. Ann was most recently at Sanofi where she held senior roles in business development and strategic venture investment. Prior to Sanofi, she was at Flagship Pioneering. Ann started her career in R&D at 3M Company, working across fields of materials, biology and engineering. Ann holds an MBA from Harvard and a PhD in Chemical Engineering from MIT. She served on the Board of Women in the Enterprise of Science and Technology and is on the Life Science Council of Springboard Enterprises.
Adam Wieschhaus, Ph.D., CFA Board Member
Adam Wieschhaus is a Director at Northpond Ventures on the firm’s life science R&D solutions, molecular diagnostics, and environmental sciences teams. Adam is a Board Director at Encodia, Inflammatix, Isolere Bio, IsoPlexis (NASDAQ: ISO), Kytopen, Ori Biotech, Slingshot Biosciences, SpeeDx, Torus Biosystems, Ultivue, and Vestaron. Adam has experience in business and science as he holds a Ph.D. from the University of Illinois College of Medicine, a B.S. in biochemistry and molecular biology from University of Georgia, and is a CFA charterholder.
KYTOPEN empowers your cells to flow from theory to therapy